GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Peter Lynch Fair Value

Pulse Biosciences (Pulse Biosciences) Peter Lynch Fair Value : $-12.94 (As of Jun. 07, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Pulse Biosciences's PEG is 1. Pulse Biosciences's 5-Year TTM EBITDA Growth Rate is 16.25. Pulse Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.80. Therefore, the Peter Lynch Fair Value for today is $-12.94.

As of today (2024-06-07), Pulse Biosciences's share price is $12.38. Pulse Biosciences's Peter Lynch fair value is $-12.94. Therefore, Pulse Biosciences's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Pulse Biosciences's Peter Lynch Fair Value or its related term are showing as below:



PLSE's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.63
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Pulse Biosciences Peter Lynch Fair Value Historical Data

The historical data trend for Pulse Biosciences's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Peter Lynch Fair Value Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pulse Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pulse Biosciences's Peter Lynch Fair Value

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Price-to-Peter-Lynch-Fair-Value falls into.



Pulse Biosciences Peter Lynch Fair Value Calculation

Pulse Biosciences's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 16.25 *-0.796
=-12.94

Pulse Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Pulse Biosciences  (NAS:PLSE) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 16.25 instead of 15 in this case.

Pulse Biosciences's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=12.38/-12.94
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulse Biosciences Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (Pulse Biosciences) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Executives
Robert W Duggan director, 10 percent owner 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy officer: Chief Commercial Officer 50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson director 3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner officer: CFO & EVP Admin. and Finance CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray director C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono director
Ed Ebbers officer: EVP & GM, Dermatology 3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D director C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg director 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow officer: CFO & SVP Admin. and Finance 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588

Pulse Biosciences (Pulse Biosciences) Headlines